Cargando…
Comparative assessment of angiotensin receptor blockers in different clinical settings
Cardiovascular and renal disease can be regarded as progressing along a sort of continuum which starts with cardiovascular risk factors (hypertension, diabetes, dyslipidemia, smoking, etc), evolves with progression of atherosclerotic lesions and organ damage, and then becomes clinically manifest wit...
Autores principales: | Verdecchia, Paolo, Angeli, Fabio, Repaci, Salvatore, Mazzotta, Giovanni, Gentile, Giorgio, Reboldi, Gianpaolo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788599/ https://www.ncbi.nlm.nih.gov/pubmed/19997575 |
Ejemplares similares
-
The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction
por: Verdecchia, Paolo, et al.
Publicado: (2008) -
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
por: Reboldi, Gianpaolo, et al.
Publicado: (2009) -
Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
por: Angeli, Fabio, et al.
Publicado: (2021) -
The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure()
por: Angeli, Fabio, et al.
Publicado: (2023) -
Hypertension and myocarditis following COVID-19 vaccination. Two sides of the coin?()
por: Angeli, Fabio, et al.
Publicado: (2023)